Medpace Holdings Inc Überblick
Branche: Diagnostics & Research
Sektor: Healthcare
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio. Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical
Research-Überblick
Letztes Berichtsdatum 2026-07-22Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Medpace Holdings Inc (MEDP): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- MEDP · Nasdaq · MIC XNAS
- Land
- United States
- Handelswährung
- USD
- Branche
- Diagnostics & Research
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-07-22
Primärquellen
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-07-22
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Medpace Holdings Inc für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $2.5B (reported). Net income/share was $4.31. Operating income was $146.8M (+16% YoY).
Revenue
$2.5B
reported
Net income/share
$4.31
reported
Operating income
$146.8M
+16% YoY
Net income
$121.4M
reported
Was sich verändert hat
- Revenue reported to $2.5B.
- Operating income +16% YoY to $146.8M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Bericht öffnen
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
SEC filing
10-Q
Jul 23, 2026
SEC filing
8-K
Jul 22, 2026
SEC filing
10-Q
Apr 23, 2026
SEC filing
8-K
Apr 22, 2026
Earnings release
Earnings release
Apr 22, 2026
SEC filing
10-K
Feb 10, 2026
SEC filing
8-K
Feb 09, 2026
Earnings release
Earnings release
Feb 09, 2026
SEC filing
10-Q
Oct 23, 2025
SEC filing
8-K
Oct 22, 2025
Earnings release
Earnings release
Oct 22, 2025
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings?
Headline from Yahoo Finance: Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings?
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
Headline from Yahoo Finance: Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
Will Medpace’s (MEDP) Revenue Beat and Guidance Hike Change Medpace Holdings' (MEDP) Narrative
Headline from Yahoo Finance: Will Medpace’s (MEDP) Revenue Beat and Guidance Hike Change Medpace Holdings' (MEDP) Narrative.
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Headline from Yahoo Finance: CON vs. MEDP: Which Stock Should Value Investors Buy Now?
If You Invested $1000 In Medpace Holdings Stock 10 Years Ago, You Would Have This Much Today
Headline from Benzinga: If You Invested $1000 In Medpace Holdings Stock 10 Years Ago, You Would Have This Much Today.
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
Headline from Yahoo Finance: Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why.
Gewinn je Aktie
Score 5.00/5
Medpace Holdings Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Eigenkapitalrendite
Score 3.61/5
Medpace Holdings Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Score 4.81/5
Medpace Holdings Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Score 1.82/5
Medpace Holdings Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.
Finanzkennzahlen
Jährlich
Quartalsweise
Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen